Riskpilot← Back to searchSign inGet full accessImprova Plastikkirurgi AB
ABActiveOrg 5567048813Linnégatan 9-11Medical specialists activities · NACE 8622Est. 200610-19 employees
Revenue 2024
SEK 12,6M
-3% vs 2023
EBITDA margin
17.8%
-6% vs 2023
Equity ratio
25.1%
Financial strength
Net profit 2024
SEK 1,9M
+1% vs 2023
| Revenue | SEK 12,6M | -3% |
| EBITDA | SEK 2,2M | -6% |
| Net profit | SEK 1,9M | +1% |
| Total assets | SEK 15,9M | -12% |
| Equity | SEK 4M | +88% |
| Employees | — | — |
Legal name
Improva Plastikkirurgi AB
Org number
5567048813
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
30 maj 2006
Share capital
SEK 100 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Hober, Dag Magnus
Company purpose
Bolaget ska utföra operationer inom plastikkirurgi och därmed förenlig verksamhet.
Address
Linnégatan 9-11
Phone
+4684114340
Email
info@improva.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 19 503 | 18 798 | 17 126 | 13 012 | 12 613 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 7 752 | 6 602 | 5 573 | 2 382 | 2 247 |
| Depreciation & amort. | −557 | −361 | −471 | −444 | −396 |
| EBIT | 7 195 | 6 241 | 5 102 | 1 938 | 1 851 |
| Net financials | −1 | −4 | −4 | 9 | 15 |
| Profit before tax | 6 266 | 5 437 | 4 540 | 2 409 | 2 455 |
| Tax | −1 370 | −1 146 | −985 | −566 | −590 |
| Net profit | 4 896 | 4 291 | 3 555 | 1 843 | 1 865 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 19 042 | 19 068 | 17 093 | 18 060 | 15 859 |
| Equity | 6 424 | 5 714 | 4 270 | 2 113 | 3 978 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 328 | 3 263 | 2 174 | 5 761 | 2 283 |
| Total debt | 3 328 | 3 263 | 2 174 | 5 761 | 2 283 |
EBITDA margin
17.8%
This company
15.8%
Market median
+13% vs market
20202024
Equity ratio
25.1%
This company
38.2%
Market median
-34% vs market
20202024
Return on equity
46.9%
This company
18.4%
Market median
+155% vs market
20202024
Net profit margin
14.8%
This company
8.1%
Market median
+83% vs market
20202024
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
20202024
Debt / equity
2.99×
This company
0.62×
Market median
-382% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HH Chief Auditor | Chief Auditor | 2022 |
DM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
STUDSTON LTD
Improva Plastikkirurgi AB Board members of Improva Plastikkirurgi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hök Hans Olov Erik Forsberg | Chief Auditor | 0 companies |
| Dag Magnus Hober | Chief Executive Officer | 0 companies |
| Elena Martinetti | Board of Directors | 0 companies |
| Sophia Elisabeth Hober | Board of Directors | 0 companies |
| Johan Arthur Gustavsson | Chairman | 0 companies |